Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Patients with stage IV lung adenocarcinoma and epidermal growth factor receptor (EGFR) mutation derive clinical benefit from treatment with EGFR tyrosine kinase inhibitors (TKIs). 21150674 2011
Entrez Id: 6667
Gene Symbol: SP1
SP1
0.010 AlteredExpression disease BEFREE We also demonstrated that Sp1 was downregulated in lung adenocarcinoma cells with high invasiveness and in patients with stage IV lung adenocarcinoma. 22158040 2012
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Patients in stage IV lung adenocarcinoma with MPEs at initial diagnosis have shorter overall survival and higher EGFR mutation rate, especially for L858R, than patients who develop MPEs following disease progression. 23018906 2013
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. 24682604 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Herein, we describe a novel mutation in exon 20 of EGFR in a Chinese male non-smoker, who was diagnosed with stage IV lung adenocarcinoma and characterized by the codon 769 point mutation GTG>GCG, which translates into alanine instead of valine (p.V769A). 24908064 2014
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Low SUV max in the metastasis favors the presence of EGFR mutations in stage IV lung adenocarcinoma, and SUV max is an independent predictor of EGFR mutations. 25608155 2015
Entrez Id: 6794
Gene Symbol: STK11
STK11
0.010 Biomarker disease BEFREE Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. 25695224 2015
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.010 Biomarker disease BEFREE Somatic STK11 and concomitant STK11/KRAS mutational frequency in stage IV lung adenocarcinoma adrenal metastases. 25695224 2015
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.020 GeneticVariation disease BEFREE We identified a novel ROS1 fusion variant (TMEM106B-ROS1) in a stage IV adenocarcinoma of the lung never-smoker female patient during routine genomic profiling (FoundationOne). 25851827 2015
Entrez Id: 54664
Gene Symbol: TMEM106B
TMEM106B
0.010 GeneticVariation disease BEFREE We identified a novel ROS1 fusion variant (TMEM106B-ROS1) in a stage IV adenocarcinoma of the lung never-smoker female patient during routine genomic profiling (FoundationOne). 25851827 2015
Entrez Id: 238
Gene Symbol: ALK
ALK
0.040 GeneticVariation disease BEFREE An 86-year-old woman with stage IV lung adenocarcinoma positive for rearrangement of ALK gene was treated with alectinib. 26334220 2015
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Radiotherapy could extend survival for EGFR mutant patients with stage IV lung adenocarcinoma. 26639246 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE We retrospectively assessed patients with EGFR-mutant stage IV lung adenocarcinoma who were treated with EGFR TKIs until disease progression. 26984681 2016
Entrez Id: 56938
Gene Symbol: ARNTL2
ARNTL2
0.010 Biomarker disease BEFREE An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-Sufficiency. 27150038 2016
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Our patient was a 41-year-old woman who had never smoked and was diagnosed with stage IV adenocarcinoma of the lung with an epidermal growth factor receptor (EGFR) mutation. 28030859 2017
Entrez Id: 4233
Gene Symbol: MET
MET
0.010 Biomarker disease BEFREE MET Amplification and Response to MET Inhibitors in Stage IV Lung Adenocarcinoma. 28324883 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE EGFR exon 18 delE709_T710insD mutated stage IV lung adenocarcinoma with response to afatinib. 28625646 2017
Entrez Id: 50943
Gene Symbol: FOXP3
FOXP3
0.010 Biomarker disease BEFREE Elevated Foxp3/CD8 Ratio in Lung Adenocarcinoma Metastatic Lymph Nodes Resected by Transcervical Extended Mediastinal Lymphadenectomy. 28831395 2017
Entrez Id: 94025
Gene Symbol: MUC16
MUC16
0.010 Biomarker disease BEFREE A single-center retrospective analysis of available carcinoembryonic antigen, CA125, CA19.9, and CA27.29 levels at baseline and during treatment of stage IV lung adenocarcinoma by oncogenic driver was conducted. 28843358 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE A 66-year-old woman presented with epidermal growth factor receptor-mutant stage IV adenocarcinoma of the lung. 28887281 2017
Entrez Id: 9788
Gene Symbol: MTSS1
MTSS1
0.010 AlteredExpression disease BEFREE To evaluate the significance of MTSS1 expression on lung adenocarcinoma metastatic properties, the gain or loss of MTSS1 in in vivo and in vitro experiments were employed. 29218652 2018
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE A total of 48 patients with stage IV lung adenocarcinoma harboring susceptible EGFR mutations who received afatinib as their first-line therapy were enrolled. 29237484 2017
Entrez Id: 1956
Gene Symbol: EGFR
EGFR
0.100 GeneticVariation disease BEFREE Molecular testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion is routinely performed in patients with stage IV lung adenocarcinoma to assess their eligibility for targeted therapy. 29364576 2018
Entrez Id: 238
Gene Symbol: ALK
ALK
0.040 Biomarker disease BEFREE Molecular testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion is routinely performed in patients with stage IV lung adenocarcinoma to assess their eligibility for targeted therapy. 29364576 2018
Entrez Id: 6098
Gene Symbol: ROS1
ROS1
0.020 Biomarker disease BEFREE Molecular testing for epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) fusion is routinely performed in patients with stage IV lung adenocarcinoma to assess their eligibility for targeted therapy. 29364576 2018